When Brain MRI is Unavailable: Laboratory Testing Priority
If brain MRI is unavailable or contraindicated, obtain a comprehensive Tier 1 laboratory panel including complete blood count with differential, complete metabolic panel (with renal/hepatic function, electrolytes, glucose, calcium, magnesium), thyroid-stimulating hormone (TSH), vitamin B12, homocysteine, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) 1, 2.
Primary Laboratory Testing Strategy
The most recent Alzheimer's Association guidelines (2025) establish a multi-tiered approach to laboratory testing when neuroimaging is delayed or unavailable 2, 1, 2. This "cognitive lab panel" serves to:
- Identify treatable conditions that contribute to cognitive symptoms (infections, dehydration, hypothyroidism, vitamin B12 deficiency)
- Exclude non-neurodegenerative causes of cognitive impairment
- Guide further diagnostic workup based on initial findings
Core Tier 1 Laboratory Tests (Obtain in All Patients)
- Complete blood count (CBC) with differential
- Complete metabolic panel including:
- Renal function (creatinine, BUN)
- Hepatic function (ALT, AST, alkaline phosphatase)
- Electrolytes (sodium, potassium, chloride, bicarbonate)
- Glucose
- Calcium, magnesium, phosphate
- Thyroid-stimulating hormone (TSH)
- Vitamin B12 level
- Homocysteine level
- C-reactive protein (CRP)
- Erythrocyte sedimentation rate (ESR)
Important Clinical Context
However, laboratory tests alone cannot replace structural brain imaging. The guidelines explicitly state that structural brain imaging (MRI preferred, CT if MRI unavailable) should be obtained in almost all patients being evaluated for cognitive-behavioral syndromes 1, 3. If MRI is temporarily unavailable, proceed with:
- Immediate laboratory workup as outlined above
- Head CT scan as an interim imaging modality 2, 1
- Arrange MRI as soon as feasible, as it provides superior detection of:
- Regional atrophy patterns (hippocampal, cortical)
- Vascular contributions (infarcts, microhemorrhages, leukoaraiosis)
- Non-degenerative conditions (tumors, hydrocephalus, mass lesions)
- Cerebral amyloid angiopathy
Additional Testing Based on Clinical Presentation
Tier 2 Testing (Obtain Based on Specific Clinical Features)
If initial workup suggests specific etiologies 2:
- Autoimmune/inflammatory concerns: Antinuclear antibodies (ANA), antithyroid peroxidase (TPO), antithyroglobulin antibodies (TGA), ANCA
- Infectious considerations: HIV, syphilis (RPR, FTA-ABS), Lyme antibody
- Metabolic disorders: Methylmalonic acid (MMA), folate, ammonia, HgbA1c
- Hematologic: Vitamin B1, lead levels, SPEP/UPEP
Special Circumstances
For autoimmune encephalitis evaluation (when this is suspected clinically), CSF analysis becomes the most critical test after brain imaging 4. CSF should include:
- Cell count and differential
- Protein, glucose, CSF/serum glucose ratio
- IgG index and synthesis rate
- Oligoclonal bands
- Viral studies (HSV1/2 PCR, VZV PCR)
- Neuronal antibody panels
For diabetic foot infections (different clinical context), the guideline recommends plain radiographs first, with MRI as the study of choice for soft tissue complications 5. When MRI is unavailable, consider radionuclide bone scan combined with labeled white blood cell scan.
Critical Pitfalls to Avoid
- Do not delay treatable diagnoses: Hypothyroidism, B12 deficiency, and infections require immediate identification and treatment
- Do not assume normal labs exclude neurodegeneration: Laboratory tests primarily identify contributing factors, not the primary neurodegenerative process
- Do not skip structural imaging indefinitely: CT is acceptable temporarily, but MRI remains essential for definitive evaluation 1, 3
- Do not order indiscriminate testing: Use clinical features to guide Tier 2 and higher testing rather than ordering comprehensive panels without indication
Practical Algorithm
Step 1: Order complete Tier 1 laboratory panel immediately
Step 2: Obtain head CT if MRI truly unavailable or contraindicated
Step 3: Add targeted Tier 2 tests based on clinical presentation (age of onset, rapidity of progression, focal neurological signs, systemic symptoms)
Step 4: Arrange MRI as soon as feasible for definitive structural assessment
Step 5: Consider specialist referral if diagnosis remains uncertain after initial workup 1, 2
The strength of this recommendation comes from the 2025 Alzheimer's Association guidelines, which represent the most current and comprehensive guidance for cognitive evaluation 2, 1, 2. These guidelines emphasize that while laboratory testing is essential, it complements rather than replaces structural neuroimaging in the diagnostic evaluation.